Clinical Laboratory, The Second People's Hospital of Jingdezhen, Key Laboratory of Cell and Molecular Medicine, Jingdezhen, China.
National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China.
J Coll Physicians Surg Pak. 2024 Sep;34(9):1066-1072. doi: 10.29271/jcpsp.2024.09.1066.
To evaluate disparities in gene expression profiles between Ovarian Clear Cell Carcinoma (OCCC) and High-Grade Serous Ovarian Carcinoma (HGSOC).
A descriptive study. Place and Duration of the Study: The Second People's Hospital of Jingdezhen, Jiangxi, China, between 31st December 2017 and December 2023.
Basic and clinical diagnostic information, along with genetic test reports, were compiled from all patients within the included groups. Differential gene expression between the two cohorts was scrutinised to elucidate its clinical significance.
Comparative analysis revealed nine differentially expressed genes in OCCC relative to HGSOC, with six exhibiting significant disparities (p <0.05). These genes are implicated in pivotal cellular processes including the cell cycle, apoptosis, DNA damage repair, and the PI3K pathway. Notably, aberrant expression patterns, such as overexpression of MET and downregulation of PTEN and SMARCA4, correlated with adverse prognosis and survival outcomes in selected patients.
Distinctive gene expression profiles between OCCC and HGSOC underscore disparate tumorigenic mechanisms, thereby laying a foundation for the tailored therapeutic interventions. Further elucidation of the identified differentially expressed genes is warranted to delineate their role in OCCC pathogenesis and prognostic significance.
Ovarian clear cell carcinoma, High-grade serous ovarian cancer, Gene expression profiles, Homologous recombination repair.
评估卵巢透明细胞癌(OCCC)和高级别浆液性卵巢癌(HGSOC)之间基因表达谱的差异。
描述性研究。
中国江西省景德镇市第二人民医院,2017 年 12 月 31 日至 2023 年 12 月。
从纳入组的所有患者中汇编了基本和临床诊断信息以及基因检测报告。对两组之间的差异基因表达进行了研究,以阐明其临床意义。
比较分析显示,OCCC 与 HGSOC 相比有 9 个差异表达基因,其中 6 个具有显著差异(p<0.05)。这些基因涉及细胞周期、细胞凋亡、DNA 损伤修复和 PI3K 途径等关键细胞过程。值得注意的是,MET 的异常表达和 PTEN 和 SMARCA4 的下调与部分患者的不良预后和生存结局相关。
OCCC 和 HGSOC 之间的明显基因表达谱差异突出了不同的肿瘤发生机制,为靶向治疗干预奠定了基础。进一步阐明鉴定出的差异表达基因,以阐明它们在 OCCC 发病机制和预后意义中的作用。
卵巢透明细胞癌、高级别浆液性卵巢癌、基因表达谱、同源重组修复。